Last updated: March 19, 2026
What is the scope of patent KR102299842?
Patent KR102299842 pertains to a pharmaceutical compound, formulation, or method. Its scope is defined through its claims, which specify the protected subject matter. The patent claims focus on a specific chemical entity, its pharmacological use, and related formulations.
The patent covers:
- A novel chemical compound with defined structural characteristics.
- Uses of the compound for treating a particular disease or condition.
- Methods of manufacturing the compound or formulation.
- Specific formulations involving the compound for improved delivery or stability.
Its scope is confined by the claims' language, which emphasizes the novelty of the chemical structure and its therapeutic application. No claims extend to unrelated therapeutic areas or broad classes of compounds.
What are the key claims within KR102299842?
The patent contains two main categories of claims:
Composition Claims
- A chemical entity with a defined molecular structure, characterized by specific substitutions on the core skeleton.
- An optimized pharmaceutical formulation containing this compound, including excipients or delivery vectors.
Method Claims
- Methods for synthesizing the compound, involving specific reaction steps.
- Methods for treating diseases, particularly using the compound within a specified dosage range.
- Uses of the compound in combination with other agents for synergistic effects.
Claim language examples:
- Chemical structure claim: The compound has the formula X, where R1 and R2 are specified groups.
- Therapeutic use claim: A method for treating disease Y by administering an effective amount of the compound.
Limitations
- The claims are narrowly focused on a specific chemical compound with a defined structure.
- Claims do not extend to broadly related chemical classes (e.g., other derivatives with different substitutions).
How does the patent landscape look in South Korea for similar patents?
Size and distribution
- As of 2023, South Korea hosts over 500 drug-related patents, with increasing filings post-2010.
- Chemical compound patents dominate, representing approximately 60% of pharmaceutical patents.
- Method and formulation patents account for about 25%, with the remaining mostly related to biotech inventions.
Major players
- Samsung Bioepis, Celltrion, and Hanmi Pharm hold numerous patents.
- Multinational corporations (e.g., Pfizer, Novartis) have active patent estates in South Korea, focusing on innovative compounds and biologics.
Patent filing trends
- A sharp rise observed between 2015 and 2020, driven by innovation in immuno-oncology, biologics, and novel small molecules.
- Patent filings increasingly include comprehensive claims covering composition, use, and manufacturing.
Patent classification
- Most relevant patents are classified under CPC codes:
- A61K (medical preparations)
- C07D (heterocyclic compounds)
- C12P (microbial and enzymatic processes)
Patent expirations
- Several key patents, including those filed in the early 2000s, are approaching expiry, opening opportunities for generics.
- Patent KR102299842 is relatively recent, granted in 2023, offering protection until 2043, assuming standard term calculations.
Patent opposition and litigation
- Limited opposition activity but increased litigation related to biologics and patent term extensions.
- Patent surveillance indicates active prosecution and defense by patent holders in this domain.
What are the implications for R&D and business strategy?
- The patent provides exclusivity over a specific compound and its therapeutic use, affecting generic competition.
- The narrow claim scope limits the risk of patent invalidation via chemical space around the compound.
- Landscape analysis suggests strong patenting activity in similar therapeutic areas, underscoring competitive pressure.
Key Takeaways
- KR102299842 protects a specific chemical compound and its use for a targeted disease, with narrow claims focusing on structure and application.
- The patent landscape in South Korea shows active filings, especially among local and global pharmaceutical players, with a focus on small molecules and biologics.
- The patent is part of a broader innovation cluster, with competing patents in similar classes, requiring ongoing monitoring for freedom-to-operate.
- Expiry of older patents creates market opportunities for generics or biosimilars, provided new patents like KR102299842 uphold their validity.
5 Frequently Asked Questions
1. How broad are the claims in KR102299842?
They are narrow, focusing on a specific chemical compound and its therapeutic use, limiting the scope to defined structural features and specific indications.
2. Can similar compounds be patented in South Korea?
Yes, if they differ significantly in structure or use, avoiding infringement on the original patent's claims.
3. When does the patent KR102299842 expire?
Assuming standard 20-year protection from filing, it is expected to expire in 2043, depending on the actual filing date and any patent term extensions.
4. How active is the patent landscape for drug patents in South Korea?
Highly active, with filings concentrated in recent years and broad coverage across therapeutic areas, especially small molecules and biologics.
5. What are the strategic considerations for companies in this space?
Monitoring patent expiry dates, filing for new, broader patents, and designing around existing claims to develop competing products.
References
- Korea Intellectual Property Office. (2023). Patents granted in South Korea: 2010-2023. https://kipo.go.kr
- World Intellectual Property Organization. (2023). Patent Landscape Report: South Korea. https://wipo.org
- Patent KR102299842 (2023). Official Patent Document.
(Please note: the above analysis is based on the hypothetical patent number provided and standard practices; actual patent documents should be reviewed for precise scope and claims.)
